武田在美国血液学会(ASH)第63届年会上发布可促进血液病和肿瘤患者治疗的新研究成果

2021-12-10 国际文传 网络

公司将呈报14篇肿瘤学摘要和9篇血液学摘要,展示在现有治疗范式下促进新型药物和优化治疗的新见解

武田药品工业株式会社(Takeda Pharmaceutical Company Limited, TSE:4502/NYSE:TAK)(“武田”)今天宣布,将于2021年12月11日至14日在佐治亚州亚特兰大召开的美国血液学会(ASH)第63届年会上呈报总计23篇公司赞助的摘要。武田在血液病领域的最新研究侧重于优化患者治疗,同时为治疗选择有限或无效的患者推进新型疗法。

武田肿瘤学部门将呈报该公司治疗多发性骨髓瘤、淋巴瘤白血病的已上市产品相关数据,并就可发挥固有免疫系统优势药物的前景提供早期见解。在血液学方面,武田将呈报一系列血液病的前瞻性、事后分析和实际数据,旨在满足出血性疾病群体的广泛需求,同时研究潜在的变革性治疗选择。

武田肿瘤细胞治疗药物和治疗领域部门主管Christopher Arendt博士表示:“在武田肿瘤学部,改善患者治疗是我们所做一切的基础。在今年的ASH上,我们期待通过共享数据和呈报研究来展示我们在血液系统癌症治疗方面的深厚传统和领导地位,这些数据将有助于为我们已有药物的优化用药提供信息,所呈报的研究来自两个产品线项目,这些项目旨在推动对癌症的强效免疫治疗。尽管仍在早期阶段,但我们将不断探索这些新的治疗途径,以求战胜癌症。”

罕见遗传病和血液学部全球医学事疗主管Neil Inhaber补充道:“我们在今年ASH上呈报的血液学数据表明我们致力于促进个体化治疗策略,并引领科学创新以满足全球出血性疾病群体未获满足的需求。我们正在开发有富有前景的在研分子产品线,这些产品有望为多种罕见和危及生命的血液病带来革新性的治疗方法,除此以外,我们将继续专注于扩大我们现有产品阵容的应用,以造福更多的罕见出血性疾病患者。”

请点击此处查阅公司赞助的全部摘要清单。

rADAMTS13 (TAK-755)、modakafusp alfa (TAK-573)和subasumstat (TAK-981)均为在研化合物,尚未被美国食品药品管理局(FDA)、欧洲药品管理局(EMA)或任何其他监管部门核准使用。

 

重要提示

就本文而言,“新闻稿”指本文件、任何口头陈述、任何问答会议,以及武田药品工业株式会社(“武田”)就本新闻稿相关内容进行讨论或分发的任何书面或口头资料。本新闻稿(包括任何口头简报和与此有关的任何问答)并非是也不构成、代表或形成任何出价购买、以及收购、注册、交换、销售或处置任何证券的任何要约、邀请或征集,或在任何司法管辖区征集任何投票或批准之一部分。不得凭借本新闻稿公开发售任何股票。除非根据美国《1933年证券法》及其修订进行登记或由此取得豁免,否则不得在美国配售任何证券。本新闻稿(连同任何可能向接收方提供的进一步信息)仅用于为接收方提供信息参考用途(并非用于评估任何投资、收购、处置或任何其他交易)。任何不遵守上述限制的行为可能会违反适用证券法。

武田通过投资直接或间接所持有公司均为独立的实体。在本新闻稿中,有时出于方便的目的,使用“武田”作为武田及其子公司的统称。同样,像“我们”(主语和宾语形式)和“我们的”这类词语也是子公司的统称或代表公司的员工。这些表述也被用于没有实际意义、不涉及某个特定的公司或某些公司的场合。  

 

前瞻性陈述

本新闻稿及与之相关的所分发的任何资料可能含有与武田未来业务、未来状况和运营业绩有关的前瞻性陈述、看法或意见,包括武田的预估、预测、目标和计划。前瞻性陈述常常包含但不限于下列措辞,例如“目标”、“计划”、“认为”、“希望”、“继续”、“预计”、“旨在”、“打算”、“确保”、“将”、“可能”、“应”、“会”、“或许”、“预期”、“估计”、“预测”或类似表述或其否定形式。这些前瞻性陈述是基于对许多重要因素的假设,包括以下因素,这些因素可能导致实际结果与前瞻性陈述所表达或暗示的内容产生重大差异:武田全球业务所面临的经济形势,包括日本和美国的宏观经济环境;竞争压力和发展情况;适用法律法规的变动;包括全球医疗改革;新产品开发的内在挑战,包括临床成功的不确定性和监管当局的决策或做出决策的时机;新产品和现有产品商业成功的不确定性;制造困难或延误;利率和汇率波动;有关已售产品或候选产品安全或功效的索赔或疑问;诸如新型冠状病毒大流行之类的健康危机对武田及其顾客和供应商的影响,包括武田经营所在国家的外国政府或其业务的其他方面;已收购公司的合并后整合努力的时机和影响;能否剥离对武田运营非核心的资产和任何此类剥离的时机;以及武田向美国证券交易委员会提交的Form 20-F最新年报和其他报告中所述的其他因素,具体请查阅武田网站https://www.takeda.com/investors/sec-filings/www.sec.gov。武田不承诺更新本新闻稿中的任何前瞻性陈述或公司可能发布的任何其他前瞻性陈述,除非是法律或证券交易规则所要求。历史业绩并不能代表未来业绩,而且本新闻稿中的武田业绩或陈述并不能指代,也并非是武田未来业绩的预估、预测、担保或推测。

 

医疗信息

本新闻稿所提到的产品可能并未在所有国家上市,或可能以不同的商标进行销售,或用于不同的病症,或采用不同的剂量,或拥有不同的效力。本文中所包含的任何信息都不应被看作是任何处方药的申请、推广或广告,包括那些正在研制的药物。

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2085977, encodeId=9c9c20859e7a4, content=<a href='/topic/show?id=d49ae98971e' target=_blank style='color:#2F92EE;'>#美国血液学会#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79897, encryptionId=d49ae98971e, topicName=美国血液学会)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ca20190, createdName=wushaoling, createdTime=Sun Jul 24 07:05:21 CST 2022, time=2022-07-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1898549, encodeId=c60218985494d, content=<a href='/topic/show?id=0bdfe3394a4' target=_blank style='color:#2F92EE;'>#研究成果#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73394, encryptionId=0bdfe3394a4, topicName=研究成果)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=84fb152, createdName=xiongliangxl, createdTime=Wed Jan 12 01:05:21 CST 2022, time=2022-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1301332, encodeId=feb713013325f, content=<a href='/topic/show?id=38e32852fe' target=_blank style='color:#2F92EE;'>#ASH#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2852, encryptionId=38e32852fe, topicName=ASH)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=39a0295, createdName=kksonne, createdTime=Sun Dec 12 05:05:21 CST 2021, time=2021-12-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1424355, encodeId=072f1424355da, content=<a href='/topic/show?id=94c182929d0' target=_blank style='color:#2F92EE;'>#肿瘤患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82929, encryptionId=94c182929d0, topicName=肿瘤患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=60943920553, createdName=lanyan20020087, createdTime=Sun Dec 12 05:05:21 CST 2021, time=2021-12-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1466329, encodeId=6e65146632902, content=<a href='/topic/show?id=765c8925904' target=_blank style='color:#2F92EE;'>#血液学#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89259, encryptionId=765c8925904, topicName=血液学)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=67c86798320, createdName=hxq78318, createdTime=Sun Dec 12 05:05:21 CST 2021, time=2021-12-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1517282, encodeId=0895151e28247, content=<a href='/topic/show?id=a0176333892' target=_blank style='color:#2F92EE;'>#武田#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63338, encryptionId=a0176333892, topicName=武田)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f6da11069119, createdName=12498f17m69暂无昵称, createdTime=Sun Dec 12 05:05:21 CST 2021, time=2021-12-12, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=2085977, encodeId=9c9c20859e7a4, content=<a href='/topic/show?id=d49ae98971e' target=_blank style='color:#2F92EE;'>#美国血液学会#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79897, encryptionId=d49ae98971e, topicName=美国血液学会)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ca20190, createdName=wushaoling, createdTime=Sun Jul 24 07:05:21 CST 2022, time=2022-07-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1898549, encodeId=c60218985494d, content=<a href='/topic/show?id=0bdfe3394a4' target=_blank style='color:#2F92EE;'>#研究成果#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73394, encryptionId=0bdfe3394a4, topicName=研究成果)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=84fb152, createdName=xiongliangxl, createdTime=Wed Jan 12 01:05:21 CST 2022, time=2022-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1301332, encodeId=feb713013325f, content=<a href='/topic/show?id=38e32852fe' target=_blank style='color:#2F92EE;'>#ASH#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2852, encryptionId=38e32852fe, topicName=ASH)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=39a0295, createdName=kksonne, createdTime=Sun Dec 12 05:05:21 CST 2021, time=2021-12-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1424355, encodeId=072f1424355da, content=<a href='/topic/show?id=94c182929d0' target=_blank style='color:#2F92EE;'>#肿瘤患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82929, encryptionId=94c182929d0, topicName=肿瘤患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=60943920553, createdName=lanyan20020087, createdTime=Sun Dec 12 05:05:21 CST 2021, time=2021-12-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1466329, encodeId=6e65146632902, content=<a href='/topic/show?id=765c8925904' target=_blank style='color:#2F92EE;'>#血液学#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89259, encryptionId=765c8925904, topicName=血液学)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=67c86798320, createdName=hxq78318, createdTime=Sun Dec 12 05:05:21 CST 2021, time=2021-12-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1517282, encodeId=0895151e28247, content=<a href='/topic/show?id=a0176333892' target=_blank style='color:#2F92EE;'>#武田#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63338, encryptionId=a0176333892, topicName=武田)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f6da11069119, createdName=12498f17m69暂无昵称, createdTime=Sun Dec 12 05:05:21 CST 2021, time=2021-12-12, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=2085977, encodeId=9c9c20859e7a4, content=<a href='/topic/show?id=d49ae98971e' target=_blank style='color:#2F92EE;'>#美国血液学会#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79897, encryptionId=d49ae98971e, topicName=美国血液学会)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ca20190, createdName=wushaoling, createdTime=Sun Jul 24 07:05:21 CST 2022, time=2022-07-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1898549, encodeId=c60218985494d, content=<a href='/topic/show?id=0bdfe3394a4' target=_blank style='color:#2F92EE;'>#研究成果#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73394, encryptionId=0bdfe3394a4, topicName=研究成果)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=84fb152, createdName=xiongliangxl, createdTime=Wed Jan 12 01:05:21 CST 2022, time=2022-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1301332, encodeId=feb713013325f, content=<a href='/topic/show?id=38e32852fe' target=_blank style='color:#2F92EE;'>#ASH#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2852, encryptionId=38e32852fe, topicName=ASH)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=39a0295, createdName=kksonne, createdTime=Sun Dec 12 05:05:21 CST 2021, time=2021-12-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1424355, encodeId=072f1424355da, content=<a href='/topic/show?id=94c182929d0' target=_blank style='color:#2F92EE;'>#肿瘤患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82929, encryptionId=94c182929d0, topicName=肿瘤患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=60943920553, createdName=lanyan20020087, createdTime=Sun Dec 12 05:05:21 CST 2021, time=2021-12-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1466329, encodeId=6e65146632902, content=<a href='/topic/show?id=765c8925904' target=_blank style='color:#2F92EE;'>#血液学#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89259, encryptionId=765c8925904, topicName=血液学)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=67c86798320, createdName=hxq78318, createdTime=Sun Dec 12 05:05:21 CST 2021, time=2021-12-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1517282, encodeId=0895151e28247, content=<a href='/topic/show?id=a0176333892' target=_blank style='color:#2F92EE;'>#武田#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63338, encryptionId=a0176333892, topicName=武田)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f6da11069119, createdName=12498f17m69暂无昵称, createdTime=Sun Dec 12 05:05:21 CST 2021, time=2021-12-12, status=1, ipAttribution=)]
    2021-12-12 kksonne
  4. [GetPortalCommentsPageByObjectIdResponse(id=2085977, encodeId=9c9c20859e7a4, content=<a href='/topic/show?id=d49ae98971e' target=_blank style='color:#2F92EE;'>#美国血液学会#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79897, encryptionId=d49ae98971e, topicName=美国血液学会)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ca20190, createdName=wushaoling, createdTime=Sun Jul 24 07:05:21 CST 2022, time=2022-07-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1898549, encodeId=c60218985494d, content=<a href='/topic/show?id=0bdfe3394a4' target=_blank style='color:#2F92EE;'>#研究成果#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73394, encryptionId=0bdfe3394a4, topicName=研究成果)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=84fb152, createdName=xiongliangxl, createdTime=Wed Jan 12 01:05:21 CST 2022, time=2022-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1301332, encodeId=feb713013325f, content=<a href='/topic/show?id=38e32852fe' target=_blank style='color:#2F92EE;'>#ASH#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2852, encryptionId=38e32852fe, topicName=ASH)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=39a0295, createdName=kksonne, createdTime=Sun Dec 12 05:05:21 CST 2021, time=2021-12-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1424355, encodeId=072f1424355da, content=<a href='/topic/show?id=94c182929d0' target=_blank style='color:#2F92EE;'>#肿瘤患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82929, encryptionId=94c182929d0, topicName=肿瘤患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=60943920553, createdName=lanyan20020087, createdTime=Sun Dec 12 05:05:21 CST 2021, time=2021-12-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1466329, encodeId=6e65146632902, content=<a href='/topic/show?id=765c8925904' target=_blank style='color:#2F92EE;'>#血液学#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89259, encryptionId=765c8925904, topicName=血液学)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=67c86798320, createdName=hxq78318, createdTime=Sun Dec 12 05:05:21 CST 2021, time=2021-12-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1517282, encodeId=0895151e28247, content=<a href='/topic/show?id=a0176333892' target=_blank style='color:#2F92EE;'>#武田#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63338, encryptionId=a0176333892, topicName=武田)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f6da11069119, createdName=12498f17m69暂无昵称, createdTime=Sun Dec 12 05:05:21 CST 2021, time=2021-12-12, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=2085977, encodeId=9c9c20859e7a4, content=<a href='/topic/show?id=d49ae98971e' target=_blank style='color:#2F92EE;'>#美国血液学会#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79897, encryptionId=d49ae98971e, topicName=美国血液学会)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ca20190, createdName=wushaoling, createdTime=Sun Jul 24 07:05:21 CST 2022, time=2022-07-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1898549, encodeId=c60218985494d, content=<a href='/topic/show?id=0bdfe3394a4' target=_blank style='color:#2F92EE;'>#研究成果#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73394, encryptionId=0bdfe3394a4, topicName=研究成果)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=84fb152, createdName=xiongliangxl, createdTime=Wed Jan 12 01:05:21 CST 2022, time=2022-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1301332, encodeId=feb713013325f, content=<a href='/topic/show?id=38e32852fe' target=_blank style='color:#2F92EE;'>#ASH#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2852, encryptionId=38e32852fe, topicName=ASH)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=39a0295, createdName=kksonne, createdTime=Sun Dec 12 05:05:21 CST 2021, time=2021-12-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1424355, encodeId=072f1424355da, content=<a href='/topic/show?id=94c182929d0' target=_blank style='color:#2F92EE;'>#肿瘤患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82929, encryptionId=94c182929d0, topicName=肿瘤患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=60943920553, createdName=lanyan20020087, createdTime=Sun Dec 12 05:05:21 CST 2021, time=2021-12-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1466329, encodeId=6e65146632902, content=<a href='/topic/show?id=765c8925904' target=_blank style='color:#2F92EE;'>#血液学#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89259, encryptionId=765c8925904, topicName=血液学)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=67c86798320, createdName=hxq78318, createdTime=Sun Dec 12 05:05:21 CST 2021, time=2021-12-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1517282, encodeId=0895151e28247, content=<a href='/topic/show?id=a0176333892' target=_blank style='color:#2F92EE;'>#武田#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63338, encryptionId=a0176333892, topicName=武田)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f6da11069119, createdName=12498f17m69暂无昵称, createdTime=Sun Dec 12 05:05:21 CST 2021, time=2021-12-12, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=2085977, encodeId=9c9c20859e7a4, content=<a href='/topic/show?id=d49ae98971e' target=_blank style='color:#2F92EE;'>#美国血液学会#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79897, encryptionId=d49ae98971e, topicName=美国血液学会)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ca20190, createdName=wushaoling, createdTime=Sun Jul 24 07:05:21 CST 2022, time=2022-07-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1898549, encodeId=c60218985494d, content=<a href='/topic/show?id=0bdfe3394a4' target=_blank style='color:#2F92EE;'>#研究成果#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73394, encryptionId=0bdfe3394a4, topicName=研究成果)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=84fb152, createdName=xiongliangxl, createdTime=Wed Jan 12 01:05:21 CST 2022, time=2022-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1301332, encodeId=feb713013325f, content=<a href='/topic/show?id=38e32852fe' target=_blank style='color:#2F92EE;'>#ASH#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2852, encryptionId=38e32852fe, topicName=ASH)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=39a0295, createdName=kksonne, createdTime=Sun Dec 12 05:05:21 CST 2021, time=2021-12-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1424355, encodeId=072f1424355da, content=<a href='/topic/show?id=94c182929d0' target=_blank style='color:#2F92EE;'>#肿瘤患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82929, encryptionId=94c182929d0, topicName=肿瘤患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=60943920553, createdName=lanyan20020087, createdTime=Sun Dec 12 05:05:21 CST 2021, time=2021-12-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1466329, encodeId=6e65146632902, content=<a href='/topic/show?id=765c8925904' target=_blank style='color:#2F92EE;'>#血液学#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89259, encryptionId=765c8925904, topicName=血液学)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=67c86798320, createdName=hxq78318, createdTime=Sun Dec 12 05:05:21 CST 2021, time=2021-12-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1517282, encodeId=0895151e28247, content=<a href='/topic/show?id=a0176333892' target=_blank style='color:#2F92EE;'>#武田#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63338, encryptionId=a0176333892, topicName=武田)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f6da11069119, createdName=12498f17m69暂无昵称, createdTime=Sun Dec 12 05:05:21 CST 2021, time=2021-12-12, status=1, ipAttribution=)]

相关资讯

AJH:多发性骨髓瘤获得性1q22增益的预后意义

获得1q22增益是MM中一个重要的分子事件,与OS降低相关

Eur J Haematol:多发性骨髓瘤对一线和二线治疗的反应动力学

通过分析均质处理队列中的 M-spike 和 LC 反应,研究团队确定了关于动力学模式预后价值的重要见解。前瞻性分析可能会更多地阐明未解决的问题

Leukemia:浆细胞疾病家族史与 MGUS、多发性骨髓瘤和系统性 AL 淀粉样变性的生存率提高有关

这是第一项证明在 MGUS、MM 和系统性 AL 淀粉样变性队列中,有 PCD 家族史的患者总生存期提高的研究。需要进一步的研究来阐明家族史和生存之间关联的潜在遗传、临床和环境机制。

Lancet Oncol:卡非佐米、达雷木单抗和地塞米松治疗复发或难治性多发性骨髓瘤的疗效

与Kd方案相比,KdD方案在复发或难治性多发性骨髓瘤患者中具有明确、持续的无进展生存获益

LEUKEMIA RESEARCH:符合移植条件的多发性骨髓瘤患者自体干细胞移植前后肿瘤负荷参数与临床预后关系的回顾性分析

在MM的新药时代,ASCT前降低血清m蛋白≥90%与PFS的改善相关。该结果还提示,移植后早期的dFLC可预测其预后

拓展阅读

病例分享 | 上皮样胶质母细胞瘤一例

上皮样胶质母细胞瘤是胶质母细胞瘤的一种组织学亚型,组织学上由具有丰富的细胞质、泡状细胞核和突出的大核仁等特征的上皮样至横纹肌样细胞组成。

IVD前沿:肿瘤细胞生物标志物检测的研究现状

文章重点介绍了根据细胞内外不同的肿瘤标志物,利用电化学/荧光传感对其进行检测和分析的最新方法和现状。

Cancer Cell:许琛琦/宋保亮发现肿瘤细胞富含胆固醇的潜在机理

由于T细胞胆固醇代谢和氧化甾醇通常与其他疾病有关,新的机制和胆固醇正常化策略可能在其他地方有潜在的应用。

Nature子刊:科学家开发了“现成”的工程干细胞来治疗侵袭性脑癌

胶质母细胞瘤(GBMs)是一种高度侵袭性的脑和脊髓癌性肿瘤。

专访西湖大学蔡尚:肿瘤细胞内确实存在细菌,它们驱动了肿瘤转移

《生物世界》第一时间采访了蔡尚研究员,一起来了解这项突破性成果的研究历程,以及带给我们的启发和影响。

Sci Transl Med:摘去肿瘤细胞的“糖衣”,CAR-T即成为“炮弹”!

通过基因工程技术将T细胞激活,并装上定位导航到肿瘤的装置-肿瘤嵌合抗原受体(Chimeric Antigen Receptor, CAR),可以将T细胞这个普通“武器”改造成&